Hormone receptor positive tumors account for approximately 75% of all breast cancer diagnoses (36), and since the development of robust clinical antibodies and therapies targeting either the ER protein or the enzyme aromatase (Cyp 19a) responsible for estrogen synthesis, mortality rates for ERα +ve tumors have been successfully attenuated. Here, CYP19A1 is linked to breast cancer.